# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.
Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.